Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Pfizer Germany launches Dupuytren’s contracture awareness campaign

Website supports company's novel, first-in-class, biologic Xiapex

Pfizer Germany online Dupuytren's campaign

Pfizer Germany has launched an online campaign to raise awareness of the progressive connective tissue disorder Dupuytren's contracture.

Based around the dupuytren-loesen.de website it offers patients and their families information on the disorder, including a self-test checklist, patient stories and a series of questions to ask their doctor.

Pfizer's novel, first-in-class, biologic Xiapex (collagenase clostridium histolyticum) was approved in Europe last March to treat Dupuytren's contracture and launched in a number of European countries, including Germany, Spain and the UK, during 2011.

The pharma company said its new German online portal would help visitors to understand the disease and give them an over view of the treatment options, with and with surgery, that are available.

Dupuytren's contracture results in a patient's fingers bending towards the palm of their hand, traditionally requiring surgery to straighten them.

The condition most commonly occurs in white Europeans, affecting up to 20 per cent of men over 60 and up to 20 per cent of women over 80.

21st February 2012

From: Marketing

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
KVA Digital

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics